SANGUI BIOTECH INTERNATIONAL INC: 10-Q filed 2015-02-12
What SANGUI BIOTECH INTERNATIONAL INC reported in its quarterly report filed 2015-02-12 (fiscal Q2 2015): 24 published measures, 72 facts as tagged in accession 0001551163-15-000010.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-02-12
- Fiscal period
- fiscal Q2 2015
- Accession
- 0001551163-15-000010 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SANGUI BIOTECH INTERNATIONAL INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 193,015 | USD | |
| At 2014-06-30 | 260,589 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -64,218 | USD | |
| At 2014-06-30 | 7,276 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 93,005 | USD | |
| At 2014-06-30 | 98,148 | USD | |
| At 2013-12-31 | 143,259 | USD | |
| At 2013-06-30 | 47,764 | USD |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | -318,740 | USD | 184 |
| 2013-07-01 to 2013-12-31 | -337,419 | USD | 184 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 31,166 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 104,906 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 33,776 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 60,303 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | 280,942 | USD | 184 |
| 2013-07-01 to 2013-12-31 | 658,533 | USD | 184 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | 32,196 | USD | 184 |
| 2013-07-01 to 2013-12-31 | -242,216 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -35,811,871 | USD | |
| At 2014-06-30 | -35,455,943 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 144,803,490 | shares | 92 |
| 2014-07-01 to 2014-12-31 | 143,975,360 | shares | 184 |
| 2013-10-01 to 2013-12-31 | 136,330,014 | shares | 92 |
| 2013-07-01 to 2013-12-31 | 134,714,941 | shares | 184 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 0 | shares | 92 |
| 2014-07-01 to 2014-12-31 | 0 | shares | 184 |
| 2013-10-01 to 2013-12-31 | 0 | shares | 92 |
| 2013-07-01 to 2013-12-31 | 0 | shares | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 193,015 | USD | |
| At 2014-06-30 | 260,589 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -902 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -1,811 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -5,659 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -5,659 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 257,233 | USD | |
| At 2014-06-30 | 253,313 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 38,332 | USD | |
| At 2014-06-30 | 3,772 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 204,710 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 486,255 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 228,083 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 446,110 | USD | 184 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 31,008 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 104,508 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 33,568 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 59,891 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 41,874 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 134,977 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 70,926 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 107,234 | USD | 184 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 4,621,430 | USD | |
| At 2014-06-30 | 4,621,430 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -537,471 | USD | |
| At 2014-06-30 | -509,841 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -174,604 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -383,558 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -445,109 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -636,813 | USD | 184 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -174,604 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -383,558 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -445,109 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -636,813 | USD | 184 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -161,760 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -355,928 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -397,830 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -570,032 | USD | 184 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 162,836 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 351,278 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 157,039 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 338,644 | USD | 184 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | -37,055 | USD | 184 |
| 2013-07-01 to 2013-12-31 | 1,049 | USD | 184 |
Inspect the source
- Entity
- SANGUI BIOTECH INTERNATIONAL INC / CIK 0001104280
- Captured
- SEC response SHA-256
80929a3d07bdd3be99cfb5858d464edb9844d0e622d958ee5dce9515baeeed6f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001104280.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))